Tags

Type your tag names separated by a space and hit enter

Antioxidant and antigenotoxic role of recombinant human erythropoeitin against alkylating agents: cisplatin and mitomycin C in cultured Vero cells.
Exp Biol Med (Maywood). 2013 Aug 01; 238(8):943-50.EB

Abstract

Cisplatin (CDDP) and mitomycin C (MMC), two alkylating agents used against various solid tumours, are a common source of acute kidney injury. Thus, strategies for minimizing CDDP and MMC toxicity are of a clinical interest. In this study, we aimed to investigate the protective role of recombinant human erythropoietin (rhEPO) against oxidative stress and genotoxicity induced by CDDP and MMC in cultured Vero cells. Three types of treatments were performed: (i) cells were treated with rhEPO 24 h before exposure to CDDP/MMC (pre-treatment), (ii) cells were treated with rhEPO and CDDP/MMC simultaneously (co-treatment), (iii) cells were treated with rhEPO 24 h after exposure to CDDP/MMC (post-treatment). Our results showed that rhEPO decreased the reactive oxygen species levels, the malondialdehyde levels and ameliorated glutathione (reduced and oxidized glutathione) modulation induced by CDDP and MMC in cultured Vero cells. Furthermore, rhEPO administration prevented alkylating agents-induced DNA damage accessed by comet test. Altogether, our results suggested a protective role of rhEPO, against CDDP- and MMC-induced oxidative stress and genotoxicity, especially in pre-treatment condition.

Authors+Show Affiliations

Laboratory of Research on Biologically Compatible Compounds, Faculty of Dentistry, Monastir University, Tunisia.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23970409

Citation

Rjiba-Touati, Karima, et al. "Antioxidant and Antigenotoxic Role of Recombinant Human Erythropoeitin Against Alkylating Agents: Cisplatin and Mitomycin C in Cultured Vero Cells." Experimental Biology and Medicine (Maywood, N.J.), vol. 238, no. 8, 2013, pp. 943-50.
Rjiba-Touati K, Ayed-Boussema I, Soualeh N, et al. Antioxidant and antigenotoxic role of recombinant human erythropoeitin against alkylating agents: cisplatin and mitomycin C in cultured Vero cells. Exp Biol Med (Maywood). 2013;238(8):943-50.
Rjiba-Touati, K., Ayed-Boussema, I., Soualeh, N., Achour, A., Bacha, H., & Abid, S. (2013). Antioxidant and antigenotoxic role of recombinant human erythropoeitin against alkylating agents: cisplatin and mitomycin C in cultured Vero cells. Experimental Biology and Medicine (Maywood, N.J.), 238(8), 943-50. https://doi.org/10.1177/1535370213494643
Rjiba-Touati K, et al. Antioxidant and Antigenotoxic Role of Recombinant Human Erythropoeitin Against Alkylating Agents: Cisplatin and Mitomycin C in Cultured Vero Cells. Exp Biol Med (Maywood). 2013 Aug 1;238(8):943-50. PubMed PMID: 23970409.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Antioxidant and antigenotoxic role of recombinant human erythropoeitin against alkylating agents: cisplatin and mitomycin C in cultured Vero cells. AU - Rjiba-Touati,Karima, AU - Ayed-Boussema,Imen, AU - Soualeh,Nidhal, AU - Achour,Abdellatif, AU - Bacha,Hassen, AU - Abid,Salwa, PY - 2013/8/24/entrez PY - 2013/8/24/pubmed PY - 2014/2/5/medline KW - antioxidant property; antigenotoxic property KW - cisplatin KW - mitomycin C KW - recombinant human erythropoietin (rhEPO) SP - 943 EP - 50 JF - Experimental biology and medicine (Maywood, N.J.) JO - Exp Biol Med (Maywood) VL - 238 IS - 8 N2 - Cisplatin (CDDP) and mitomycin C (MMC), two alkylating agents used against various solid tumours, are a common source of acute kidney injury. Thus, strategies for minimizing CDDP and MMC toxicity are of a clinical interest. In this study, we aimed to investigate the protective role of recombinant human erythropoietin (rhEPO) against oxidative stress and genotoxicity induced by CDDP and MMC in cultured Vero cells. Three types of treatments were performed: (i) cells were treated with rhEPO 24 h before exposure to CDDP/MMC (pre-treatment), (ii) cells were treated with rhEPO and CDDP/MMC simultaneously (co-treatment), (iii) cells were treated with rhEPO 24 h after exposure to CDDP/MMC (post-treatment). Our results showed that rhEPO decreased the reactive oxygen species levels, the malondialdehyde levels and ameliorated glutathione (reduced and oxidized glutathione) modulation induced by CDDP and MMC in cultured Vero cells. Furthermore, rhEPO administration prevented alkylating agents-induced DNA damage accessed by comet test. Altogether, our results suggested a protective role of rhEPO, against CDDP- and MMC-induced oxidative stress and genotoxicity, especially in pre-treatment condition. SN - 1535-3699 UR - https://www.unboundmedicine.com/medline/citation/23970409/Antioxidant_and_antigenotoxic_role_of_recombinant_human_erythropoeitin_against_alkylating_agents:_cisplatin_and_mitomycin_C_in_cultured_Vero_cells_ L2 - https://journals.sagepub.com/doi/10.1177/1535370213494643?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -